The 2024 World Conference on Lung Cancer is happening in San Diego from September 7th to 10th! The WCLC website has already released some groundbreaking abstracts. Here are the key research highlights from the OA06 oral presentation session on “Novel Immunotherapy Strategies and Combination Therapies”:
OA06.03 – SAFFRON-301: Tislelizumab + Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1
OA06.04 – Phase II Study: Pembrolizumab + Itacitinib for Metastatic NSCLC Expressing PD-L1 – Long-Term Follow-Up
OA06.05 – IL15 Superagonist (N-803, Anktiva): + Checkpoint Inhibitor Prolongs OS in 2nd-line or Greater NSCLC Patients Failing CPI
Stay tuned for more updates from WCLC 2024!
